TRAX Stock Surges As Traders Pile Into Biotech Momentum

First Tracks Biotherapeutics Inc. stocks have been trading up by 14.66 percent after promising clinical trial progress boosted investor optimism.

Live Update At 17:03:40 EDT: On Friday, July 10, 2026 First Tracks Biotherapeutics Inc. stock [NASDAQ: TRAX] is trending up by 14.66%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TRAX is trading like a classic speculative biotech — big cash, big burn, and big price swings. Over the last few weeks, First Tracks Biotherapeutics Inc. climbed from around $16–$18 to close near $36, more than a 100% move. For active traders, that’s the kind of volatility that can make a month in a single morning, if you respect risk.

On the fundamentals, TRAX is not a value play. First Tracks Biotherapeutics Inc. posted a quarterly net loss of about $50M, with diluted EPS at -$1.45. Operating cash flow was roughly -$32.6M and free cash flow came in near -$32.6M as well. That’s heavy burn.

But here’s the kicker: the balance sheet shows about $248M in cash and roughly $286M in cash plus short-term investments. Total liabilities sit near $291M, yet working capital is a hefty $256M. TRAX also carries a price-to-book of about 3.14, telling traders the market is already pricing in future potential, not current earnings. For short-term trading, the key takeaway is simple — this is a high-cash, high-burn biotech whose chart is leading the story.

Why Traders Are Watching TRAX Price Action

The daily chart for TRAX reads like a case study in momentum. First Tracks Biotherapeutics Inc. spent late June chopping in the mid-teens, with closes around $16–$20. Then buyers stepped in hard. On 2026/07/09, TRAX opened at $21 and exploded to a high of $33.70, closing at $32.40. The very next day, First Tracks Biotherapeutics Inc. gapped up again, tagging $38.49 before finishing at $36.24. That’s sustained demand, not a one-candle fluke.

Intraday, the 5-minute chart shows TRAX pushing higher in the morning from the low $30s to the upper $30s, then consolidating in a tight band between roughly $36.5 and $38 for much of the afternoon. Every sharp dip toward the mid-$35s and low-$36s found buyers. For day traders, that repeated behavior matters — it defines key intraday support and resistance zones to trade against.

At the same time, the fundamentals of First Tracks Biotherapeutics Inc. remind everyone what this really is: a speculation on future biotech success. Negative return on equity around -19.6% and negative return on assets near -17.4% show that TRAX is nowhere near profitability. The story is about the runway, not the income statement. With hundreds of millions in cash and no long-term debt on the books, traders are betting First Tracks Biotherapeutics Inc. has enough time to attempt meaningful progress. As long as that belief holds, TRAX can remain a favored momentum vehicle.

Conclusion

TRAX lives in that familiar biotech sweet spot for active traders — huge swings, clear levels, and a balance sheet that buys time, not comfort. First Tracks Biotherapeutics Inc. is losing money quickly, but it’s also holding a very large cash cushion and strong working capital, which helps explain why trading appetite has been so strong on this breakout.

From a technical standpoint, First Tracks Biotherapeutics Inc. has shifted from a grinding base in the teens to an aggressive breakout above $30, with intraday action supporting the move rather than rejecting it. TRAX is now a stock where traders watch every pullback toward prior support areas in the mid-$30s and previous breakout zones in the high $20s to low $30s. Failures at those levels can unwind gains fast; successful holds can launch the next leg.

The message from the TRAX tape is simple: this is not a slow-and-steady name. It’s a trader’s stock. As Tim Sykes likes to say, “Volatility is your best friend or your worst enemy, depending on whether you respect it.” In a setup like TRAX, discipline around entries and exits matters just as much as spotting the pattern in the first place; as millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.”. For First Tracks Biotherapeutics Inc. and TRAX, the opportunity is real, but so is the risk. Use the chart, know the fundamentals, and remember you’re trading a story that’s still being written — not a finished business. This analysis is for educational and research purposes only, not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks